Award
NIH Reporter #5UG3DA062088-02
Evaluation of psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients who continue to use illicit opioids
Recipient
New York University School of Medicine
Award Amount
$3,172,763.00
Ceiling
$3,172,763.00
Awarded
September 05, 2025
Identifier
5UG3DA062088-02
A research project funded by the National Institute on Drug Abuse to evaluate psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients continuing illicit opioid use, involving a randomized adaptive trial with 240 participants.
Description
This project investigates the potential of psilocybin to treat opioid use disorder (OUD) in patients who continue to use illicit opioids despite methadone treatment. The study involves a randomized, adaptive trial with 240 participants from opioid treatment programs in New York and New Mexico. Participants will receive a single dose of psilocybin as an adjunct to ongoing treatment, with follow-up over 24 weeks. The trial aims to assess safety, efficacy, and neuropsychopathology related to OUD.